| 0.3091 -0.01 (-3.16%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.4  |
1-year : | 0.44 |
| Resists | First : | 0.34 |
Second : | 0.38 |
| Pivot price | 0.33  |
|||
| Supports | First : | 0.28 | Second : | 0.23 |
| MAs | MA(5) : | 0.32 |
MA(20) : | 0.33 |
| MA(100) : | 0.41 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 43.5 |
D(3) : | 51.5 |
| RSI | RSI(14): 40.7 |
|||
| 52-week | High : | 4 | Low : | 0.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ADVB ] has closed above bottom band by 16.3%. Bollinger Bands are 35.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.35 - 0.35 | 0.35 - 0.35 |
| Low: | 0.29 - 0.29 | 0.29 - 0.29 |
| Close: | 0.31 - 0.31 | 0.31 - 0.31 |
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, a fully automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cells (CTCs) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also provides microfluidic biochips comprising A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips that are designed to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include the A+CTCE kit, which is used to identify epithelial circulating tumor cells and is determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; the A+CTCM kit, which is used to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; the A+EMT, which is used to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and the A+CM, which is used to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
Wed, 21 Jan 2026
Advanced Biomed Appeals Nasdaq Delisting, Plans Reverse Split - TipRanks
Tue, 30 Dec 2025
Advanced Biomed stock rises after divesting Hong Kong subsidiary By Investing.com - Investing.com UK
Tue, 30 Dec 2025
Advanced Biomed sells Hong Kong subsidiary for $23,000 - Investing.com
Tue, 30 Dec 2025
Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary - Yahoo Finance
Tue, 30 Dec 2025
Biotech firm offloads Hong Kong unit and IP for just $23,000 - Stock Titan
Fri, 06 Jun 2025
advanced biomed enters $25 million stock purchase agreement - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 22 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 77.5 (%) |
| Held by Institutions | 1.2 (%) |
| Shares Short | 364 (K) |
| Shares Short P.Month | 180 (K) |
| EPS | -0.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35.3 % |
| Return on Equity (ttm) | -165 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -1.82 |
| PEG Ratio | 0 |
| Price to Book value | 2.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|